313 related articles for article (PubMed ID: 29361687)
1. Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Ulivi P; Canale M; Passardi A; Marisi G; Valgiusti M; Frassineti GL; Calistri D; Amadori D; Scarpi E
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29361687
[TBL] [Abstract][Full Text] [Related]
2. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.
Manceau G; Imbeaud S; Thiébaut R; Liébaert F; Fontaine K; Rousseau F; Génin B; Le Corre D; Didelot A; Vincent M; Bachet JB; Chibaudel B; Bouché O; Landi B; Bibeau F; Leroy K; Penault-Llorca F; Van Laethem JL; Demetter P; Tejpar S; Rossi S; Mosakhani N; Osterlund P; Ristamäki R; Sarhadi V; Knuutila S; Boige V; André T; Laurent-Puig P
Clin Cancer Res; 2014 Jun; 20(12):3338-47. PubMed ID: 24771647
[TBL] [Abstract][Full Text] [Related]
3. Expression levels of miR-143-3p and -424-5p in colorectal cancer and their clinical significance.
Sahami-Fard MH; Kheirandish S; Sheikhha MH
Cancer Biomark; 2019; 24(3):291-297. PubMed ID: 30883340
[TBL] [Abstract][Full Text] [Related]
4. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Laurent-Puig P; Grisoni ML; Heinemann V; Liebaert F; Neureiter D; Jung A; Montestruc F; Gaston-Mathe Y; Thiébaut R; Stintzing S
Clin Cancer Res; 2019 Jan; 25(1):134-141. PubMed ID: 30108104
[TBL] [Abstract][Full Text] [Related]
5. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
[TBL] [Abstract][Full Text] [Related]
6. The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab.
Fiala O; Pitule P; Hosek P; Liska V; Sorejs O; Bruha J; Vycital O; Buchler T; Poprach A; Topolcan O; Finek J
Tumour Biol; 2017 Jul; 39(7):1010428317709283. PubMed ID: 28714375
[TBL] [Abstract][Full Text] [Related]
7. Identification of non-invasive biomarkers for chronic atrophic gastritis from serum exosomal microRNAs.
Liu H; Li PW; Yang WQ; Mi H; Pan JL; Huang YC; Hou ZK; Hou QK; Luo Q; Liu FB
BMC Cancer; 2019 Feb; 19(1):129. PubMed ID: 30736753
[TBL] [Abstract][Full Text] [Related]
8. A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer.
Poel D; Gootjes EC; Bakkerus L; Trypsteen W; Dekker H; van der Vliet HJ; van Grieken NCT; Verhoef C; Buffart TE; Verheul HMW
Cancer Med; 2020 Oct; 9(20):7558-7571. PubMed ID: 32864858
[TBL] [Abstract][Full Text] [Related]
9. Identification of serum miR-30a-5p as a diagnostic and prognostic biomarker in colorectal cancer.
Sun Y; Yang B; Lin M; Yu H; Chen H; Zhang Z
Cancer Biomark; 2019; 24(3):299-305. PubMed ID: 30829615
[TBL] [Abstract][Full Text] [Related]
10. An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality.
Slattery ML; Herrick JS; Mullany LE; Valeri N; Stevens J; Caan BJ; Samowitz W; Wolff RK
Int J Cancer; 2015 Jul; 137(2):428-38. PubMed ID: 25484364
[TBL] [Abstract][Full Text] [Related]
11. An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer.
Kiss D; Machackova T; Souckova K; Fabian P; Krepelkova I; Svoboda M; Kiss I
In Vivo; 2021; 35(5):2809-2814. PubMed ID: 34410972
[TBL] [Abstract][Full Text] [Related]
12. Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer.
Zhang J; Raju GS; Chang DW; Lin SH; Chen Z; Wu X
Cancer; 2018 Feb; 124(4):785-796. PubMed ID: 29112225
[TBL] [Abstract][Full Text] [Related]
13. The correlation of circulating pro-angiogenic miRNAs' expressions with disease risk, clinicopathological features, and survival profiles in gastric cancer.
Peng W; Liu YN; Zhu SQ; Li WQ; Guo FC
Cancer Med; 2018 Aug; 7(8):3773-3791. PubMed ID: 30003708
[TBL] [Abstract][Full Text] [Related]
14. Association between common genetic variants in pre-microRNAs and prognosis of advanced gastric cancer treated with chemotherapy.
Tahara T; Okubo M; Shibata T; Kawamura T; Sumi K; Ishizuka T; Nagasaka M; Nakagawa Y; Arisawa T; Ohmiya N; Hirata I
Anticancer Res; 2014 Sep; 34(9):5199-204. PubMed ID: 25202115
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
16. MTUS1 and its targeting miRNAs in colorectal carcinoma: significant associations.
Ozcan O; Kara M; Yumrutas O; Bozgeyik E; Bozgeyik I; Celik OI
Tumour Biol; 2016 May; 37(5):6637-45. PubMed ID: 26643896
[TBL] [Abstract][Full Text] [Related]
17. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
[TBL] [Abstract][Full Text] [Related]
18. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer.
Yuan D; Li K; Zhu K; Yan R; Dang C
Cancer Biol Ther; 2015; 16(2):268-75. PubMed ID: 25629978
[TBL] [Abstract][Full Text] [Related]
19. Circulating microRNAs as novel biomarkers of ALK-positive nonsmall cell lung cancer and predictors of response to crizotinib therapy.
Li LL; Qu LL; Fu HJ; Zheng XF; Tang CH; Li XY; Chen J; Wang WX; Yang SX; Wang L; Zhao GH; Lv PP; Zhang M; Lei YY; Qin HF; Wang H; Gao HJ; Liu XQ
Oncotarget; 2017 Jul; 8(28):45399-45414. PubMed ID: 28514730
[TBL] [Abstract][Full Text] [Related]
20. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
